Business context and reporting period
The supplied filing is IsoRay, Inc.’s Form 10-Q for the quarter ended March 31, 2017, the third quarter of fiscal 2017, with nine-month results through that date. It is not a Perspective Therapeutics filing for 2016 Q3, as specified in the request metadata.
IsoRay manufactures and sells Cesium-131 brachytherapy seeds. Its sales are concentrated in prostate brachytherapy; distributors in Italy and Russia reported no revenue for the quarter.
Financial results
| Metric (USD millions, except per-share data) | Three months ended March 31, 2017 | Three months ended March 31, 2016 | Nine months ended March 31, 2017 | Nine months ended March 31, 2016 |
|---|---|---|---|---|
| Net product sales | 1.282 | 1.199 | 3.391 | 3.649 |
| Gross profit / margin | 0.293 / 23% | 0.067 / 6% | 0.340 / 10% | 0.177 / 5% |
| Operating loss | (1.389) | (1.327) | (4.443) | (3.828) |
| Net loss | (1.360) | (1.195) | (4.307) | (3.526) |
| Loss per share | (0.02) | (0.02) | (0.08) | (0.06) |
- Quarterly sales increased 7% year over year; nine-month sales declined 7%. Quarterly prostate sales rose 14%, while other brachytherapy sales fell 25%. Nine-month prostate and other brachytherapy sales declined 5% and 20%, respectively.
- Quarterly gross margin improved to 23% from 6%, reflecting lower product costs and staffing savings. Sales and marketing expense rose to $0.530 million from $0.301 million; research and development expense included $0.161 million net collaboration costs.
- At March 31, cash and cash equivalents were $5.100 million and certificates of deposit were $5.307 million. Working capital was $10.783 million and the current ratio was 10.46. Total assets were $13.941 million; total liabilities were $1.694 million. The filing reports no debt.
- Nine-month operating cash use was $4.499 million, versus $2.676 million a year earlier. Investing cash use was $0.531 million; financing cash use was $0.009 million. Cash declined $5.039 million from fiscal-year opening.
Material changes and management commentary
- Management attributed quarterly sales growth to sales-team changes, renewed marketing, new accounts, and re-engagement with prior customers. It said sales-manager turnover in two territories weighed on the quarter.
- Management said fiscal 2017 cash requirements were expected to be about $0.8 million higher than the prior year, mainly because of filled sales positions and increased rebranding and marketing costs. It expected existing cash and certificates of deposit to cover operating needs through the remainder of fiscal 2017 and fiscal 2018.
- The company did not expect to meet its 20% fiscal 2017 revenue-growth target. Management said cash-flow break-even might be reached in three to five years if growth targets are achieved, but cautioned that there is no assurance of that outcome.
- Management planned about $0.260 million of additional production-automation investment over the following 11 months. Any new facility construction depends on financing.
- The company may seek equity, strategic collaboration, debt, or other financing; management warned that any equity financing could be discounted and dilute shareholders.
Risks, contingencies, and unusual items
- Five customers accounted for about 46% of nine-month revenue, with one customer contributing about 23%; the filing warns that losing a major customer could materially hurt revenue.
- A securities class action was settled and dismissed with prejudice in March 2017. The $3.538 million settlement fund was paid by insurers.
- A shareholder derivative case remained pending, with defendants’ motion to dismiss outstanding. A separate equity-plan class action had a settlement in principle: seek shareholder approval of the 2014 plan and prior grants, cancel the 2016 plan, and resolve plaintiffs’ legal fees; the fee amount was not yet estimable.
- After missing a property-development covenant, the company paid the Port of Benton $0.198 million on May 4, 2017. That amount was recorded in accounts payable at March 31. The company said it was no longer subject to the redevelopment plan, but remained subject to property covenants.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Investor facts to verify
- Confirm the filing identity and period: this is IsoRay’s fiscal 2017 third-quarter 10-Q, not a Perspective Therapeutics 2016 Q3 filing.
- Track cash burn and whether the reported liquidity remains sufficient, especially given the stated reliance on financing for future needs and facility plans.
- Assess whether quarterly sales improvement continues and whether customer concentration and sales volatility remain significant.
- Follow the equity-plan litigation settlement, required shareholder votes, and any associated legal fees.
- Verify progress and spending on automation, and whether management’s conditional break-even outlook remains achievable.